As expected, the tumor burden and 7-week mortality were similar in global Tlr9–/– mice and FRC-Tlr9–/– mice between anti–PD-1 and ODN+anti–PD-1 treatments (Figure 6, A–D). The gene discussed is TLR9; the disease is neoplasm.